R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group

A O Gang, C Strøm, M Pedersen, F d'Amore, L M Pedersen, Anne Bukh, B B Pedersen, M B Moeller, L S Mortensen, O V Gadeberg, S Ingeberg, T Mourits-Andersen, Stanislaw Pulczynski, P D Nully Brown

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Optimal treatment of young patients with high-risk diffuse large B-cell lymphoma (DLBCL) remains a matter of debate and requires improvement. The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with addition of etoposide (CHOEP) has in other patient groups been shown to be effective. Further improvement has been accomplished with the use of rituximab in combination with the regimens every 2 weeks (R-CHOP-14, R-CHOEP-14). The aim of the present retrospective population-based study was to compare R-CHOP-14 with R-CHOEP-14 in a cohort of high-risk patients aged 18-60 years with two or more risk factors (stage III-IV, elevated lactate dehydrogenase levels, performance status 2-4). To our knowledge, this is the first study comparing these two regimens in this patient group.
OriginalsprogEngelsk
TidsskriftAnnals of Oncology
Vol/bind23
Udgave nummer1
Sider (fra-til)147-53
Antal sider7
ISSN0923-7534
DOI
StatusUdgivet - 2012

Fingeraftryk Dyk ned i forskningsemnerne om 'R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group'. Sammen danner de et unikt fingeraftryk.

Citationsformater